Antimicrobial resistance (AMR) is on course to overtake cancer and account for 10 million deaths a year by 2050. Already, 700,000 people die from drug-resistant infections (“superbugs”) each year. AMR could cost the global economy up to $100 trillion – and push 28 million more people into poverty.

The life science industry – research-based, generics, biotech and diagnostic companies – is researching solutions to avoid medical progress being thrown back to the dark ages as AMR continues to undermine treatments for infectious diseases. A new coalition of over 100 such companies, the AMR Industry Alliance, is uniquely collaborating in this fight.

 

Research is under pressure to ensure we are not thrown into the dark ages of AMR

 

This involves preserving the efficacy of existing antibiotics and developing new ones. So far, AMR Industry Alliance says companies have invested at least $2 billion in 2016 in R&D to counter AMR.

A 2017 report commissioned by the German government estimates that governments have given $500 million to R&D for new antibiotics. As of June 2018, four new antibiotic drug applications have been submitted and 42 new antibiotics with the potential to treat serious bacterial infections are in clinical development. But this is not enough. The report recommends the development of one new high-need antibiotic a year. This is a very big ask, given the fragility of the market and the lack of robust incentives.

 

Incentives for innovation in new treatments

 

Thankfully, a global consensus has emerged, agreeing that AMR requires concerted collaboration to provide incentives for innovation to achieve an impactful, long-term change on the pipeline of new products and strengthen patients’ access to the appropriate treatments.

Incentives are needed to overcome the challenge of high-risk investments that are difficult to sustain under the current conditions where new antibiotics will remain on the shelves as reserve and for use as a last resort, meaning there is very limited and unpredictable economic return on these products. Incentives can also address the problem that antibiotics are generally undervalued by reimbursement systems relative to the benefits they bring society.

 

Cutting-edge diagnostics for effective antibiotic use

 

Diagnostics play a key role for the optimal diagnosis of a patient, for the optimal cost-efficient functioning of healthcare systems, and for the benefit of public health.

They guide the effective use of antibiotics by identifying the infectious agent, as well as any potential resistance to antibiotics, in order to help clinicians prescribe the most appropriate treatment with the shortest time delay. They also reduce inappropriate use while helping to ensure that existing drugs remain effective.

Diagnostics are crucial to implementing informative and effective AMR surveillance systems that collect and analyse important information on pathogen identification and resistance in countries or regions. Novel methods, such as molecular syndromic testing, can provide rapid and accurate results for many different pathogens all at the same time, maximising patient health outcomes, saving time and money and avoiding repeated testing. New diagnostics adapted to low- and middle-income countries are also urgently needed.

But to accelerate effective innovation from biotechs, diagnostics firms and R&D pharma companies, governments need to implement new, alternative market structures that provide more dependable and sustainable market models. The present market is fragile so there is an urgent need to act.

Fundamental changes are needed to encourage R&D efforts towards novel diagnostics and therapeutics, to simplify and facilitate market access of innovative health products and to develop educational and communication programs around AMR for health workers as well as the general public.